anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Systemic sclerosis (also called scleroderma, SSc) is a chronic autoimmune disorder characterized by excessive collagen deposition leading to skin fibrosis and various internal organ manifestations. The emergent diagnostics and therapeutic strategies for scleroderma focus on early detection and targeted interventions to improve patient outcomes and quality of life. Diagnostics for SSc have evolved significantly in recent years, driven by advancements in serological markers and imaging techniques. Autoantibody profiling, especially antinuclear antibodies (ANA) and specific scleroderma-associated autoantibodies, aids in identifying subsets of scleroderma and predicting disease progression. Furthermore, novel imaging modalities, such as high-frequency ultrasonography and optical coherence tomography, enable early detection of skin fibrosis and internal organ involvement, enhancing the diagnostic precision and allowing for tailored management. Therapeutic strategies for SSc are multifaceted, targeting immune dysregulation, vascular abnormalities, and fibrotic processes. Emerging biologic agents have shown promise in clinical trials, including monoclonal antibodies directed against key cytokines involved in fibrosis, such as transforming growth factor-β (TGF-β) and interleukin-6 (IL-6). Additionally, small-molecule inhibitors that disrupt fibrotic pathways, like tyrosine kinase inhibitors, have exhibited potential in limiting collagen deposition and preventing disease progression. Stem cell therapy, cell ablation and gene editing techniques hold great potential in regenerating damaged tissue and halting fibrotic processes. Early intervention remains crucial in managing SSc, as irreversible tissue damage often occurs in advanced stages. Novel diagnostic methods, such as biomarkers and gene expression profiling, are being explored to identify individuals at high risk for developing progressive severe disease and intervene proactively. Furthermore, patient-tailored therapeutic approaches, employing a combination of immunosuppressive agents and targeted anti-fibrotic therapies, are being investigated to improve treatment efficacy while minimizing adverse effects. The emergent diagnostics and therapeutic strategies in scleroderma are transforming the management of this challenging disease. Nevertheless, ongoing research and clinical trials are needed to optimize the efficacy and safety of these novel approaches in the complex and diverse spectrum of SSc manifestations.
Hemodialysis removes cefdinir from the body. In patients maintained on chronic hemodialysis, the recommended initial dosage regimen is a 300 mg or 7 mg/kg dose every other day. At the conclusion of each hemodialysis session, 300 mg (or 7 mg/kg) should be given. Subsequent doses (300 mg or 7 mg/kg) are then administered every other day.

After mixing, the suspension can be stored at controlled room temperature (20° to 25°C/68° to 77°F). The container should be kept tightly closed, and the suspension should be shaken well before each administration. The suspension may be used for 10 days, after which any unused portion must be discarded.
PROBLEM TO BE SOLVED: To obtain the subject cosmetic giving luster when applied, not having stickiness, having good spread, adhesion, retention of the luster and storing stability, and excellent in moist touch and its retention, by compounding a fatty acid dextrin ester, a heavy-duty liquid isoparaffin and an oily component. SOLUTION: The subject cosmetic is obtained by containing (A) a fatty acid dextrin ester (for example, palmitic acid dextrin ester) in an amount of, preferably, 2-25 wt.%, (B) a heavy-duty liquid isoparaffin in an amount of, preferably, 5-60 wt.%, and (C) an oily component being liquid at an ordinary temperature. The preparation is preferably obtained through a method which can effectively prevent the preparation from gelling or destroy the gelation. The component B has preferably an average molecular weight of 700-1,400. A compound, or a combination of two or more compounds, selected from a liquid paraffin, squalane or the like is used as the component C, and a formulation amount is, preferably, 20-70 wt.%. A colorant such as a pigment and a dyestuff, a thickening agent, a cosmetic component, an antiseptic agent or the like can be formulated to the cosmetic.
Subjects aged 60 years or older at the time of re-vaccination, who previously received 1 dose of the Fluarix™ vaccine in study NCT00321763, received 1 dose of Fluarix™ vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
Two U.S. multicenter, double-blind, placebo controlled studies were conducted in 316 adult patients with daytime and nighttime heartburn. Patients reported 5 or more periods of moderate to very severe heartburn during the placebo treatment phase the week prior to randomization. Patients were confirmed by endoscopy to have no esophageal erosions. 

The percentage of heartburn free daytime and/or nighttime periods was greater with 20 mg rabeprazole sodium delayed-release tablets compared to placebo over the 4 weeks of study in Study RAB-USA-2 (47% vs. 23%) and Study RAB-USA-3 (52% vs. 28%). The mean decreases from baseline in average daytime and nighttime heartburn scores were significantly greater for rabeprazole sodium 20 mg as compared to placebo at week 4. Graphical displays depicting the daily mean daytime and nighttime scores are provided in Figures 2 to 5.

In addition, the combined analysis of these two studies showed 20 mg rabeprazole sodium delayed-release tablets significantly improved other GERD-associated symptoms (regurgitation, belching, and early satiety) by week 4 compared with placebo (all p values < 0.005).

A dose of 20 mg rabeprazole sodium delayed-release tablets also significantly reduced daily antacid consumption versus placebo over 4 weeks (p<0.001).

The recommended dosage of rabeprazole sodium delayed-release tablets is 20 mg once daily for 4 weeks.
Overview of design: To address the specific aims of this study we will recruit and study two groups of obese subjects, selected to be similar in age, gender and BMI. Based on the results of an oral glucose tolerance test (OGTT) and hyperinsulinemic-glucose clamp, one group will be obese and insulin resistant (OIR) and one will be obese and insulin sensitive (OIS). Subjects will undergo measurement of body fat and fat distribution, oral glucose tolerance, in vivo insulin sensitivity, percutaneous needle biopsies of subcutaneous abdominal and gluteal fat and in vivo measurement of SVC and adipocyte turnover using the D2O DNA labeling technique. Adipocyte size and the expression of pro-inflammatory cytokines and adipokines will be compared in the two groups. Primary cultures of preadipocytes will be derived from subjects and proliferation and differentiation measured in vitro and compared to in vivo measures.

Measurement of adipocyte proliferation and differentiation in vivo: The stable isotope technique of Hellerstein et al. for the measurement of slowly dividing cells is based on the incorporation of deuterium oxide (D2O) into DNA. This method has been used to estimate rates of turnover of adipocytes and stromal vascular cells in healthy normal volunteers. It has not, to date, been employed to compare groups of subjects who may differ in their adipogenic propensity. A major objective of the study, therefore, is to evaluate the utility of this approach for quantifying in vivo differences in adipocyte and SVC turnover between groups that vary by insulin sensitivity and to compare the in vivo measures obtained using this technique with in vitro measures of adipogenesis.
Vanadium is a strategic metal that has many important industrial applications and is generated by the use of burning fossil fuels, which inevitably leads to their release into the environment, mainly in the form of oxides. The wastes generated by their use represent a major health hazard. Furthermore, it has attracted attention because several genotoxicity studies have shown that some vanadium compounds can affect DNA; among the most studied compounds is vanadium pentoxide, but studies in vivo with oxidation states IV and III are scarce and controversial. In this study, the genotoxic and cytotoxic potential of vanadium oxides was investigated in mouse bone marrow cells using structural chromosomal aberration (SCA) and mitotic index (MI) test systems. Three groups were administered vanadium(IV) tetraoxide (V2O4) intraperitoneally at 4.7, 9.4 or 18.8 mg/kg, and three groups were administered vanadium(III) trioxide (V2O3) at 4.22, 8.46 or 16.93 mg/kg body weight. The control group was treated with sterile water, and the positive control group was treated with cadmium(II) chloride (CdCl2). After 24 h, all doses of vanadium compounds increased the percentage of cells with SCA and decreased the MI. Our results demonstrated that under the present experimental conditions and doses, treatment with V2O4 and V2O3 induces chromosomal aberrations and alters cell division in the bone marrow of mice.
Postoperative pain (POP) is a major clinical challenge. Local anesthetics (LAs), including amide-type LAs, ester-type LAs, and other potential ion-channel blockers, are emerging as drugs for POP management because of their effectiveness and affordability. However, LAs typically exhibit short durations of action and prolonging the duration by increasing their dosage or concentration may increase the risk of motor block or systemic local anesthetic toxicity. In addition, techniques using LAs, such as intrathecal infusion, require professional operation and are prone to catheter displacement, dislodgement, infection, and nerve damage. With the development of materials science and nanotechnology, various LAs delivery systems have been developed to compensate for these disadvantages. Numerous delivery systems have been designed to continuously release a safe dose in a single administration to ensure minimal systemic toxicity and prolong pain relief. LAs delivery systems can also be designed to control the duration and intensity of analgesia according to changes in the external trigger conditions, achieve on-demand analgesia, and significantly improve pain relief and patient satisfaction. In this review, we summarize POP pathways, animal models and methods for POP testing, and highlight LAs delivery systems for POP management. STATEMENT OF SIGNIFICANCE: Postoperative pain (POP) is a major clinical challenge. Local anesthetics (LAs) are emerging as drugs for POP management because of their effectiveness and affordability. However, they exhibit short durations and toxicity. Various LAs delivery systems have been developed to compensate for these disadvantages. They have been designed to continuously release a safe dose in a single administration to ensure minimal toxicity and prolong pain relief. LAs delivery systems can also be designed to control the duration and intensity of analgesia to achieve on-demand analgesia, and significantly improve pain relief and patient satisfaction. In this paper, we summarize POP pathways, animal models, and methods for POP testing and highlight LAs delivery systems for POP management.
The invention provides a preparation method of a Dicranostigma leptopodum extract perfusate. The method comprises the following steps: adding water to a Dicranostigma leptopodum extract, decocting, mixing filtrates, and concentrating to obtain a concentrate; and extracting with ethanol, removing ethanol, adding benzyl alcohol and Tween-80 to the above obtained ethanol removed medicinal liquid, adding injection water to a full dose, and sterilizing to obtain the Dicranostigma leptopodum extract perfusate. The invention also provides an application of the perfusate in the preparation of medicines for treating cow mastitis. The Dicranostigma leptopodum extract perfusate adopting the Dicranostigma leptopodum extract as an effective component has very good heat clearing, detoxifying, bacterium resisting, inflammation eliminating and virus resisting effects. The perfusate is a pure traditional Chinese medicinal preparation, contains no chemical components, and is in favor of the safety of dairy products. Products produced through extraction and preparation integrated production have the advantages of stable properties and controllable quality, and are in favor of industrial production. The perfusate has the advantages of definite effect, no residual or toxic side effects, and realization of use in the lactation period as an effective medicine for treating clinic mastitis of cows, and becomes a good substitute of antibiotics.
For example, and without limitation, an embodiment of the subject matter described herein includes a computer-implemented method. The computer-implemented method includes electronically receiving data indicative of a healthcare service provided to a particular patient. The received data includes at least one of data indicative of an activity within a proximity of the patient, or data inputted by the patient and relevant to determining an aspect of the healthcare service. The computer-implemented method includes converting the received data into information indicative of one or more units of service. The computer-implemented method includes estimating probable fees and costs incurred to date in providing the healthcare service. The estimating is responsive to the information indicative of units of healthcare service provided to the patient. The computer-implemented method includes outputting information indicative of the probable fees and costs incurred to date providing the healthcare service.
The present invention relates to DNA encoding Acrp30, of vertebrate (e.g. mammalian) origin, and particularly of human and rodent origin. The present invention further relates to isolated, recombinantly produced or synthetic DNA which hybridizes to the nucleotide sequences described herein and RNA transcribed from the nucleotides sequence described herein. In addition, the invention relates to expression vectors comprising DNA encoding Acrp30, which is expressed when the vector is present in an appropriate host cell. The invention further relates to isolated, recombinantly produced or synthetic mammalian Acrp30 of vertebrate (e.g., mammalian) origin, and particularly of human and rodent origin. Also encompassed by the present invention is an inhibitor or enhancer of Acrp30. The present invention further relates to a method of identifying inhibitors or enhancers of Acrp30. Isolation of Acrp30 makes it possible to detect Acrp30 or adipocytes in a sample (e.g., test sample). In addition, the present invention relates to a method of regulating the energy balance (e.g., nutritional status) of a mammal by administering to the mammal an inhibitor or enhancer of the Acrp30. The present invention further relates to a method of modulating insulin production in a mammal comprising administering Acrp30 to the mammal.
All patients on this protocol will be treated with standard of care melphalan conditioning followed by autologous hematopoietic stem cell transplant (AHCT). After AHCT, if patients are randomized to the experimental arm, CYT107 will be initiated and will continue for 4 weeks. CYT107 will be administered subcutaneously starting on D+1. Two doses will be given during the first week, and then CYT107 will be administered weekly for 3 more weeks for a total of 5 doses.
It is estimated that China has a population of over 10 million infected with HCV and also a highly variable HCV genotype geographic distribution. A simple, universal, non-genotype-specific treatment regimen is preferred for anti-HCV treatment in clinical practice and public health. KW-136 and sofosbuvir are potent anti-HCV agents targeting at different HCV proteins, namely, nonstructural protein 5A and 5B, respectively. The combination regimen of KW-136 and sofosbuvir is expected to completely suppress HCV replication in subjects chronically infected with HCV and achieve a sustained virologic response (SVR12), namely, HCV not detected or below a predefined limit in plasma, 12 or 24 weeks after cessation of treatment.

In a previous phase 2 exploratory study, an all-oral, ribavirin-free regiment of KW-136, an investigational HCV NS5A inhibitor, combined with sofosbuvir, demonstrated a \~99% SVR12 in treatment-naive adult subjects chronically infected with major genotypes of HCV found in China, including those with compensatory cirrhosis. This phase 3 study aimed to confirm the efficacy and safety of this combined regimen in a large scale of target patient population, including interferon-experienced subjects. This simple, uniform regimen is expected to be the solution to HCV eradication in China from the perspective of public health.
Patients with SAH (see eligibility criteria below). Planned enrollment: 50 patients.
As part of the ENTAiER trial: In group sessions á 5 patients with a qualified therapist: In the first 3 months twice a week, in the second 3 months once a week. Recommendation to practice at home on at least 3 days per week (optimal, practice daily). They are supported by an eurythmy manual and an exercise video. This supplements the regular care.
1,247,712. Phenylglycine derivatives. BRISTOL-MYERS CO. 19 Aug., 1968 [18 Aug., 1967], No. 5020/71. Divided out of 1,247,717. Heading C2C. The invention comprises compounds of the formula in which R is C 1 -C 10  alkyl and Y is H or a group in which Z is -CCl 3  or C 1 -C 10  alkoxy. These compounds may be prepared by reacting a compound of formula with an excess of t-butoxycarbonyl azide and excess of magnesium oxide in aqueous dioxane solution to give the compound of the formula given above in which Y is H and treating this compound with an approximately equimolar amount of a trichloracetyl halide or an alkyl chloroformate to give a compound in which Z in the group is -CCl 3  or C 1 -C 10  alkoxy, respectively. The starting materials are prepared by the method described in copending Specification 1,247,714.
YL205 is provided as the lyophilized powder, 160 mg/vial. Adcanced solid tumors patients will be given YL205 by intravenously once every 3 weeks (Q3W) as a cycle at several dose levels.
Standard HIV counseling and testing plus blood drawn for CD4 testing at time of HIV diagnosis. CD4 results are reported to participants via telephone within 1 week. Additionally, a trained peer counselor provides supplemental counseling at the time of diagnosis and at the 1 week telephone follow-up.
BACKGROUND: Intestinal necrosis in uremic patients has been reported but is rare.
CASE PRESENTATION: A 56-year-old male patient who underwent long-term regular haemodialysis was admitted to the hospital due to involuntary shaking of the limbs and nonsense speech. The patient's symptoms improved after continuous blood purification under heparin anticoagulation, rehydration, sedation, and correction of electrolyte disturbances. However, the patient experienced a sudden onset of abdominal pain and a rapid decrease in blood pressure; high-dose norepinephrine were required to maintain his blood pressure. A plain abdominal radiograph performed at bedside showed intestinal dilation. Colonoscopy revealed inflammation and oedema of the entire colon, with purulent secretions and multiple areas of patchy necrosis. The cause of intestinal ischaemia was not clear.
CONCLUSIONS: Although rare, previous causes of uremic colitis have been reported. As the patient developed abdominal pain before the onset of shock and the necrosis was seen on colonoscopy, we suspect that this is a case of fulminant uremic colitis.
A method for providing a therapy plan includes receiving a dataset. The dataset maps an examination object including a first tissue area at at least one first timepoint. The first tissue area is identified in the dataset as a first state. A second state is specified for the first tissue area. A therapy plan for a therapy apparatus is determined by application of a model to input data. A change in the first tissue area between the at least one first timepoint and at least one second timepoint is createable by the control of the therapy apparatus in accordance with the therapy plan. The model maps the first state to the second state and/or the second state to the first state. The therapy plan is provided as output data of the model.
SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
Building on family, twin and adoption studies suggesting that substantial aspects of personality are heritable, research under this protocol explores potential genetic influences on normal personality dimensions. We have previously reported associations between variation in neurotransmitter system genes and variation in personality traits, both across and within families, in a sample of the general population. This study involves collecting personality data and DNA samples from related individuals, primarily male siblings and female siblings, but also including parents. Genetic tests performed on these samples will continue to focus on variations in genes, which potentially affect brain neurotransmission. In some cases, participants are recontacted to specifically investigate whether identified variations in neurotransmitter system genes actually affect neurotransmission. Large population samples are needed in this research, particularly since a new epidemiologically standard population sample will be obtained. This research has the potential to advance knowledge of genetic influences on human behavior that may be relevant both to normal personality and to psychopathology.
INTRODUCTION: Neurogenic Heterotopic ossification (NHO) is a potential sequalae and a detrimental complication following neurological insult. It is characterized by formation of localized gradually progressive, peri-articular lamellar bone formation in extra-skeletal tissues. We would like to report a rare case of heterotopic ossification involving all 4 limbs, in which we tried to restore joint mobility to improve his functional status so that he could perform his daily tasks.
CASE PRESENTATION: We present a case of a 33-year-old bed ridden male, diagnosed with NHO involving all 4 limbs (bilateral hip, right knee, right shoulder, left elbow). The patient had a crippled posture, significant pain and impaired range of motion hampering movement of all four limbs which prevented him from lying down supine, sitting, walking and performing activities of daily living. After three surgeries, the patient achieved wheelchair mobilization and upright posture with the assistance of calipers.
CONCLUSION: The management of NHO requires a multidisciplinary approach involving orthopaedic surgeons, neurologists & rehabilitation specialists. Prognosis of NHO depends on factors such as extent of ossification, underlying neurological condition & patients overall health.
Intervention group: intraoperative mean blood pressure target \> 80 mmHg. Treatment of hypotension (defined as a mean blood pressure of below 80 mmHg) using intravenous bolus or continuous infusion of vasopressors, or fluids using a dedicated algorithm considering the pulse pressure or stroke volume variation and the mini fluid challenge to optimize mean blood pressure values.
This application provides a microsphere suitable for tissue engineering that comprises connective tissue growth factor (CTGF). Also provided is a matrix, material or scaffold suitable for tissue engineering that comprises connective tissue growth factor (CTGF) and basic fibroblast growth factor (bFGF). Additionally, methods of treating skin of a human are provided. The methods comprise administering to the skin microspheres comprising a growth factor that increases fibroblast proliferation or collagen, elastin, or glycosaminoglycan synthesis. Further provided are the use of the above microspheres for the treatment of the skin of a human. Additionally, this application proves the use of the above microsphere for the manufacture of a medicament for the treatment of the skin of a human.